Agilent Technologies, Inc. $A Shares Sold by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. reduced its stake in Agilent Technologies by 1.7%, selling 5,894 shares, and now holds approximately 0.12% of the company valued at $39.9 million.
• Several institutional investors increased their stakes significantly in Agilent Technologies during the first quarter, with Generation Investment Management boosting their position by 19.8% and GAMMA Investing LLC growing theirs by an astounding 15,648.1%.
• Agilent Technologies' shares increased by 2.2% recently, with the stock valued at $126.88, and the company reported quarterly earnings of $1.37 per share, meeting analysts' expectations.

Alliancebernstein L.P. lessened its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 1.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 341,196 shares of the medical research company's stock after selling 5,894 shares during the period. Alliancebernstein L.P. owned about 0.12% of Agilent Technologies worth $39,913,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Banque Transatlantique SA boosted its position in Agilent Technologies by 16,138.0% in the 1st quarter. Banque Transatlantique SA now owns 64,952 shares of the medical research company's stock worth $7,022,000 after purchasing an additional 64,552 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Agilent Technologies by 3.9% during the 1st quarter. Advisors Asset Management Inc. now owns 6,835 shares of the medical research company's stock valued at $800,000 after buying an additional 258 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Agilent Technologies during the 1st quarter valued at approximately $25,988,000. Amundi lifted its position in shares of Agilent Technologies by 0.8% during the 1st quarter. Amundi now owns 1,096,994 shares of the medical research company's stock valued at $120,307,000 after buying an additional 8,710 shares in the last quarter. Finally, Ancora Advisors LLC lifted its position in shares of Agilent Technologies by 33.6% during the 1st quarter. Ancora Advisors LLC now owns 19,063 shares of the medical research company's stock valued at $2,230,000 after buying an additional 4,791 shares in the last quarter. Hedge funds and other institutional investors own 87.41% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on A shares. TD Cowen increased their target price on Agilent Technologies to $150.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Evercore ISI decreased their target price on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research report on Thursday, August 28th. UBS Group decreased their target price on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Robert W. Baird increased their target price on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Finally, Leerink Partners increased their target price on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Friday, May 30th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $139.25.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares of the company's stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by company insiders.

Agilent Technologies Stock Down 2.8%

A stock traded down $3.54 during trading on Friday, hitting $123.19. 1,250,804 shares of the company's stock were exchanged, compared to its average volume of 1,689,851. The business has a 50-day moving average price of $119.76 and a two-hundred day moving average price of $115.87. The stock has a market capitalization of $34.92 billion, a price-to-earnings ratio of 28.92, a PEG ratio of 3.94 and a beta of 1.24. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.